Objective-Platelets express a functional ubiquitin-proteasome system. Mass spectrometry shows that platelets contain several deubiquitinases, but whether these are functional, modulate the proteome, or affect platelet reactivity are unknown. Approach and Results-Platelet lysates contained ubiquitin-protein deubiquitinase activity hydrolyzing both Lys 48 and Lys 63 polyubiquitin conjugates that was suppressed by the chemically unrelated deubiquitinase inhibitors PYR41 and PR619. These inhibitors acutely and markedly increased monoubiquitination and polyubiquitination of the proteome of resting platelets. PYR41 (intravenous, 15 minutes) significantly impaired occlusive thrombosis in FeCl 3 -damaged carotid arteries, and deubiquitinase inhibition reduced platelet adhesion and retention during high shear flow of whole blood through microfluidic chambers coated with collagen. Total internal reflection microscopy showed that adhesion and spreading in the absence of flow were strongly curtailed by these inhibitors with failure of stable process extension and reduced the retraction of formed clots. Deubiquitinase inhibition also sharply reduced homotypic platelet aggregation in response to not only the incomplete agonists ADP and collagen acting through glycoprotein VI but also to the complete agonist thrombin. Suppressed aggregation was accompanied by curtailed procaspase activating compound-1 binding to activated IIb/IIIa and inhibition of P-selectin translocation to the platelet surface. Deubiquitinase inhibition abolished the agonist-induced spike in intracellular calcium, suppressed Akt phosphorylation, and reduced agoniststimulated phosphatase and tensin homolog phosphatase phosphorylation. Platelets express the proteasome-associated deubiquitinases USP14 and UCHL5, and selective inhibition of these enzymes by b-AP15 reproduced the inhibitory effect of the general deubiquitinase inhibitors on ex vivo platelet function. 
P latelet activation underlies thrombotic cardiovascular disease, responsible for significant death and disability in the developed world, 1, 2 and modulation of platelet activation is an established therapeutic target for these diseases. Platelets are anucleate and lack transcription, so their activation is transduced by the proteome delivered to them during thrombopoiesis, although this is augmented by limited de novo protein synthesis. 3 Conversely, inhibitors show that platelets also possess a limited ability to reduce their proteome through the ubiquitin-proteasome proteolytic system that participates in their production during thrombopoiesis and contributes to the functions of activated cells. [4] [5] [6] Analysis of the platelet proteome by quantitative mass spectrometry 7 not only identifies the expected components of the ubiquitin ligase system but also identifies deubiquitinases at high copy number. These enzymes might modify the pattern of ubiquitin chains conjugated to the platelet proteome, but this is unstudied.
See accompanying editorial on page 2489
Covalent modification of proteins with ubiquitin is dynamic and reversible with 6 families of evolutionarily conserved deubiquitinases hydrolyzing these monomeric and polymeric ubiquitin-protein adducts. 8 Deubiquitinases are isopeptidases that play pivotal roles in ubiquitin-mediated signaling pathways, and deubiquitinase inhibitors alter diverse cellular functions, as anticipated from the range of processes using ubiquitin adduction. Accordingly, some deubiquitinase inhibitors have therapeutic potential. 9 The general deubiquitinase inhibitor PR619 10 promotes autophagy, protein aggregation, and the unfolded protein response in nucleated cells. 11, 12 A small-molecule inhibitor of E1 ubiquitin-activating enzyme, PYR41, 13 suppresses arachidonate-stimulated adhesion and migration of tumor cells on a collagen surface, 14 angiotensin II-mediated dendritic cell activation, 15 and nuclear factor-κB activation in tumor cells. 13 However, PYR41 also leads to accumulation of ubiquitinated proteins ex vivo and in vitro by inhibiting deubiquitinases. 16 The novel small-molecule inhibitor b-AP15 that is highly specific for the proteasome-associated deubiquitinases USP14 and UCHL5 displays potent antitumor activity and induces cytotoxicity in multiple myeloma cells resistant to the proteasome inhibitor bortezomib. 17, 18 Inhibition of the proteasome quells the ultimate step of ubiquitin-mediated protein degradation, but layers of regulated processes lie upstream of this proteolytic machine. We determined whether ubiquitination of the platelet proteome was dynamic and whether modification of ubiquitin-protein adducts contributes to platelet function. We found platelets contain active deubiquitinases that regulate ex vivo platelet aggregation, adhesion, and activation and that deubiquitinase inhibition reduced occlusive thrombosis in vivo. Specific inhibition of proteasome-associated deubiquitinases recapitulated the modulation of platelet function by general deubiquitinase inhibitors, highlighting the active participation of the proteasome in platelet activation. 5 Our data suggest that the modulation of platelet deubiquitinase activity is a potential new approach to antiplatelet therapy.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Platelets Express Functional Deubiquitinases
The platelet proteome is decorated with polyubiquitin chains that direct select proteins to the proteasome for degradation after activation, 5 suggesting that the pattern of ubiquitin conjugation should be dynamic. We treated platelet lysates with HA-tagged ubiquitin vinyl sulfone, 19 which covalently adducts active deubiquitinases during hydrolysis of this isopeptidase substrate, to determine whether platelets contain enzymes that actively modify conjugated polyubiquitin chains. We found that platelets contain ≤10 differently sized proteins labeled by this mechanism-based deubiquitinase inhibitor ( Figure 1A ). The general deubiquitinase inhibitor PYR41 and a structurally unrelated deubiquitinase inhibitor PR619 decreased catalytic labeling of each of these active platelet deubiquitinases. We directly assayed polyubiquitin deconjugating enzymatic activity in platelet lysates to find whether platelets expressed ubiquitin conjugate isopeptidase enzymatic activity that was inhibited by PYR41 and PR619 ( Figure 1B) .
Polyubiquitin chains most commonly polymerize through K 48 , and in general, these proteins are then recognized by the proteasomal system. Alternatively, polymerization through K 63 generally alters protein distribution. Deubiquitinases are selective for these isomeric ubiquitin chain linkages, 8 and platelet lysates catalyzed rapid disassembly of heptameric K 48 -linked ( Figure 1C ) and K 63 -linked ( Figure 1D ) polyubiquitin chains. The deubiquitinase inhibitors, PYR41 and PR619, protected some of the short K 48 polymers from proteolysis but not the K 63 polymer. Treating intact platelets for 30 minutes with either PYR41 or PR619 increased the content of polyubiquitin-conjugated proteins relative to pattern of conjugation found in quiescent platelets ( Figure 1E ). The increase in decorated proteins was apparent for most of the protein bands but was prominent in the more slowly migrating proteins that no longer appeared as distinct bands. Thus, inhibition of deubiquitinase activity shows that quiescent platelets must rapidly and continuously cycle ubiquitin through polymeric ubiquitin chains adducting select proteins.
Deubiquitination of the Platelet Proteome Promotes Thrombosis
We investigated whether deubiquitinase inhibition altered platelet function during arterial thrombosis created by injuring the wall of murine carotid arteries in situ with FeCl 3 . This damage results in rapid platelet accretion with formation of a platelet-rich occlusive barrier at the site of injury. 20, 21 Typically, complete cessation of flow through the artery occurred 12 minutes after the brief exposure to ectopic FeCl 3 in animals treated with the dimethyl sulfoxide vehicle (Figure 2A ). However, disruption of ubiquitin metabolism by intravenous injection of PYR41 15 minutes before vessel injury significantly lengthened the time to occlusion to 26 minutes, consistent with the delay induced by inhibition of the platelet proteasome. 5 We modeled platelet accretion ex vivo by flowing whole human blood through a collagen-coated microfluidic channel that generates high shear. Fluorescently labeled platelets in whole blood were immobilized along the length of the chamber, as shown in a typical video frame captured at the distal end of the chamber after 3 minutes of flow ( Figure 2B ; Video I in the online-only Data Supplement). Preincubating blood with either PYR41 or PR619 reduced the number of platelets adhering in the collagen-coated chamber by 80% ( Figure 2C ), and this difference was significant (P<0.05). These outcomes show that the adhesive phenotype of activated platelets depends on rapid deubiquitination of their proteome.
Deubiquitinase Inhibition Impairs the Function of Isolated Platelets
We purified and washed human platelets and then assayed a range of functions to determine whether deubiquitinase inhibitors directly act on platelets to alter their function and not just nucleated cells of the vasculature or blood. Aggregometry showed that aggregation induced by the incomplete agonists ADP ( Figure 3A ) or collagen ( Figure 3B ) was strongly suppressed by PYR41 and abolished after pretreatment with PR619. These 2 inhibitors had an identical effect on the more robust aggregation induced by the complete agonist thrombin ( Figure 3C ). These effects were stimulus-dependent because neither compound by itself promoted aggregate . The inhibitory effect of PYR41 and PR619 was optimal at 0.2 U of thrombin and was lost at higher concentrations (data not shown).
Outside-in signaling induces cytoskeletal rearrangement, with extension of filopodia and lamellapodia, when platelets interact with a glass substrate. Thrombin stimulation enhances these responses, which was apparent in individual video frames captured by total internal reflection microscopy of fluorescently labeled platelets ( Figure 3H ; Video II in the online-only Data Supplement). Both PYR41 and PR619 abolish the adhesion and spreading of unstimulated platelets, while significantly ( Figure 3I ) reducing these responses after thrombin stimulation.
Agonist Activation of Glycoprotein αIIbβ3 Is Reduced by Deubiquitinase Inhibition
Agonist stimulation alters the conformation of the platelet β3 integrin αIIbβ3 glycoprotein complex that enhances platelet-platelet and platelet-endothelial cell interactions. 22 The antibody procaspase activating compound-1 (PAC-1) recognizes a neoepitope in activated αIIbβ3, and thrombin stimulation greatly increased PAC-1 binding to the surface of washed human platelets compared with quiescent control cells (Figures 4A). Pretreating platelets with PYR41 for 15 minutes suppressed PAC-1 binding to such an extent that αIIbβ3 activation was not statistically distinct from unstimulated platelets ( Figure 4B ). PR619 also effectively reduced thrombin-stimulated expression of PAC-1 ( Figure 4E and 4F) . Inhibition of deubiquitinase activity by either PYR41 ( Figure 4C and 4D) or PR619 ( Figure 4G and 4H) also fully suppressed thrombin stimulation of α-granule secretion detected by the translocation of P-selectin from these granules to the platelet surface. Thrombin at the concentration used above activates platelets primarily through the protease-activated receptor-1, but activation of platelets through a second G-protein-coupled receptor, the P2Y 12 receptor for ADP, was also abolished by 
Proteasome-Associated Deubiquitinases Regulate Platelet Activation
Platelets not only contain several cytoplasmic deubiquitinases but also abundantly express the proteasome-associated deubiquitinases USP14 and UCHL5 at 3100 and 1500 copies per platelet, respectively. 7 Specific inhibitors of USP14 and UCHL5 have been developed since the levels of these 2 enzymes are upregulated in many cancers 23 and are considered to be targets for potential anticancer therapies. A small-molecule inhibitor, b-AP15, was recently identified 17 that specifically inhibited just these 2 proteasome-bound deubiquitinases without affecting the catalytic activities of soluble deubiquitinases. This inhibitor is potent and available to intracellular enzyme with b-AP15 inhibiting hydrolysis of fluorogenic ubiquitin substrate by the 19S subunit of the proteasome with an IC50 of just 6.5 µmol/L. 24 We treated washed platelets with b-AP15 to determine whether this inhibitor induced the accumulation of high-molecular weight ubiquitin-conjugated proteins ( Figure 5A ). We confirmed that platelets contained both USP14 and UCHL5 targets of b-AP15 by recovering platelet proteasomes by high-speed centrifugation and then Western blotting the proteins of the isolated proteasome ( Figure 5B ). Next, we determined whether USP14 and UCHL5 regulated platelet function to find whether b-AP15 inhibited thrombin-( Figure 5C ), collagen-( Figure 5D ), and ADP-( Figure 5E ) induced aggregation. The inhibitory effect of b-AP15 on agonist-induced platelet aggregation was significant for each of these agonists ( Figure 5F ), and the data show that platelet aggregation was not affected by b-AP15 treatment alone. The small-molecule inhibitor b-AP15 also inhibited thrombin-induced αIIbβ3 activation detected by PAC-1 binding ( Figure 5G ), as well as P-selectin exocytosis from platelet α-granules ( Figure 5H ). Pretreatment with b-AP15 also blocked ADP-induced αIIbβ3 activation ( Figure IIIA in the online-only Data Supplement). USP14 and UCHL5 inhibition had a more profound effect on collagen-induced aggregation 3 15 minutes later to a surgically exposed murine carotid artery as described in Methods section. Time to complete cessation of blood flow in the murine carotid artery was determined using intravital microscopy (n=5 experimental and 3 control; **P≤0.01). B, PYR41 or PR619 pretreatment blocked platelet adhesion to collagen at high shear. Calcein AM-labeled blood, treated or not with PYR41 or PR619, was perfused over immobilized type 1 collagen fibrils (150 µg/mL) at 67.5 dyne/cm 2 for 3 minutes. Images are representative fields taken from 3 independent experiments that yielded similar results (n=3). C, Area of platelet attachment after PYR41 or PR619 treatment. Platelet area in (B) was quantified by ImagePro plus software, and results are plotted as area of platelet adhesion in square microns (n=3; ***P≤0.001).
( Figure 5C ) than the general deubiquitinase inhibitors, so we tested the effect of inhibition of these enzymes on platelet adhesion to collagen under static conditions. b-AP15 pretreatment reduced the number of platelets adhering to a exposed collagen-coated surface ( Figure IIIB in the online-only Data Supplement), suggesting a vital role of proteasome-associated deubiquitinases in mediating platelet interactions with exposed collagen.
Inhibition of Platelet Deubiquitinases Modulates Signaling Downstream of Thrombin and Collagen Receptors
Akt (protein kinase B) is a serine/threonine kinase that is an established downstream effector of phosphatidylinositol 3-kinase (PI3K). 25 Platelets express 2 Akt isoforms, Akt1
and Akt2, 26, 27 where targeted deletion of Akt1 diminishes responses to both thrombin and collagen, 28, 29 whereas Akt2 deletion suppresses secretion and thrombosis. 30 We determined whether deubiquitinase activity modulated Akt activation. Stimulation with thrombin resulted in time-dependent increase in Akt phosphorylation at both serine 473 and threonine 308 residues, which was reduced by pretreatment with either PYR41, PR619, or b-AP15 ( Figure 6A ). Pretreating platelets with any of the 3 deubiquitinase inhibitors resulted in equivalent reduction of collagen-induced phosphorylation of Akt serine 473 and threonine 308 ( Figure 6B ), although the inhibition of threonine 308 phosphorylation by either agonist was more profound than the reduction at serine 473 . In platelets, Akt activation is both PI3K dependent and independent, but sustained Akt activation is PI3K dependent. PI3K isoform-β is essential to promote PLCγ-2 activation downstream of glycoprotein VI-FcRγ receptor 32 that leads to intracellular calcium release critical for sustained αIIbβ3 activation necessary for ex vivo clot retraction 33, 34 and consolidation in vivo. 32, 35 Collagen-induced intracellular calcium release was inhibited when platelets were preincubated with deubiquitinase inhibitors before stimulation by collagen ( Figure 6C ). Deubiquitinase inhibitors also significantly reduced fibrin clot retraction ( Figure 6D ), suggesting impaired outside-in signaling from integrin αIIbβ3.
Phosphatase and tensin homolog (PTEN) on chromosome 10 is a negative regulator of PI3K/Akt signaling 36 that reduces collagen-dependent platelet activation. 37 PTEN phosphatase activity is negatively regulated in nucleated cells by phosphorylation at serine 380 , 38, 39 although this has not been extended yet to platelets. We observed that both thrombin and collagen increased PTEN phosphorylation at this residue ( Figure 6E ) and that pretreatment with deubiquitinase inhibitors reduced agonist-dependent increase in PTEN phosphorylation and inactivation.
Discussion
We found that protein ubiquitination in platelets is a dynamic process where acute inhibition of deubiquitinase activity caused a significant increase in ubiquitin modification of the proteome of quiescent cells within just a few minutes. This change occurred both with general deubiquitinase inhibitors and in response to b-AP15 inhibition of UCHL5 and USP14 of the platelet proteasome. Because these changes were apparent in the absence of agonist stimulation and intracellular signaling, we conclude that the proteome of quiescent platelets undergoes a continuous, and rapid, cycle of ubiquitination and deubiquitination. Notably, deubiquitinase inhibition was without detectable effect on the total content of platelet proteins ( Figure IV in the online-only Data Supplement), nor did complete loss of platelet proteasome proteolytic activity alter the complement of platelet proteins (beyond release of filamin A to the soluble fraction). 5 We found that protein deubiquitination promotes platelet reactivity. The general deubiquitinase inhibitors PYR41 or PR619 blocked inside-out activation of αIIbβ3 integrin, homotypic aggregation, and inhibited adhesion to collagen under flow at high shear. PYR41 additionally blocked the formation of occlusive platelet-rich thrombi in damaged carotid arteries. Inhibition of deubiquitinase activity suppressed the extension of membrane protrusions and cell spreading, and deubiquitinase inhibition blocked α-granule release and hence blocked the agonist-stimulated increase of P-selectin on the platelet surface. Continual remodeling and turnover of ubiquitin modification of platelet proteins is thus a positive element in the transition from quiescent cells to activated platelets that is necessary for thrombosis. We conclude that the widespread suppression of stimulated platelet function by deubiquitinase inhibition means that ubiquitin modification of the proteome must maintain platelets in an inactive state and that either restructuring of the existing polyubiquitin decoration of the platelet proteome or that recycled ubiquitin is produced to allow its addition to new targets-Western blotting shows that intracellular free ubiquitin is limiting-releases tonic ubiquitin inhibition of platelet signaling and activation. (P4D1, n=3) . B, Platelet proteasomes contained UCH14 and UCLH5. Western blot of platelet proteasomes recovered by high-speed centrifugation (178 000g; 2 hours). C, Proteasome-associated deubiquitinases promote stimulated platelet aggregation. b-AP15 pretreatment inhibited thrombin-(C; n=3), collagen-(D; n=3n=3), and ADP-induced aggregation (E; n=3n=3). F, b-AP15-mediated inhibition of stimulated platelet aggregation is statistically significant (n=3; ***P≤0.001, **P≤0.01, and *P≤0.05). G, b-AP15 pretreatment suppressed stimulated αIIbβ3 activation. Flow cytometry using procaspase activating compound-1 (PAC-1) antibody binding to platelets treated or not with b-AP15 and stimulated or not with 0.2 U of thrombin (n=3). H, b-AP15 pretreatment reduced P-selectin surface expression on activation. Flow cytometry using phycoerythrin (PE)-conjugated anti-P-selectin antibody binding to platelets treated or not with b-AP15 with or without 0.2 U of thrombin (n=3). December 2015
Deubiquitinase inhibitors affected signaling downstream of G-protein-coupled receptors and the glycoprotein VI receptor for collagen. Thrombin-and collagen-induced Akt phosphorylation was reduced not only by both the pan deubiquitinase inhibitors PYR41 and PR619 but also by the specific inhibitor of proteasome-associated deubiquitinase activity, b-AP15. Activation of PI3K and its effector, Akt, is essential in most aspects of collagen-induced platelet activation and thrombin-and collagen-induced αIIbβ3 integrin outside-in signaling. The effect of PI3K/Akt axis on thrombin-induced aggregation is only seen at lower thrombin concentrations and is overcome at high agonist concentrations. 33, 40 Akt activation in platelets is both PI3K dependent and PI3K independent 41 ; however, PI3K isoform-β is mandatory for glycoprotein VI-FcRγ receptor-mediated Akt activation, platelet aggregation, intracellular calcium release, and degranulation. 42 We found that ubiquitin remodeling is an integral component of this cascade.
We attribute at least part of the reduction in phosphorylated Akt after pretreatment with deubiquitinase inhibitors to the upregulation of PTEN phosphatase activity. PTEN negatively regulates Akt activation, which negatively regulates collagen-induced platelet activation, 37 by converting phosphatidylinositol 3,4,5-trisphosphate to phosphatidylinositol 4,5-bisphosphate. Phosphoinositide-dependent protein kinase-1 is activated by an increase in phosphatidylinositol 3,4,5-trisphosphate after PI3K activation, and activated phosphoinositide-dependent protein kinase-1 phosphorylates Akt at residue threonine 308 . 43 Platelet-specific knockdown of phosphoinositide-dependent protein kinase-1 and subsequent loss in Akt phosphorylation reduces thrombin-induced platelet aggregation, clot retraction, and thrombosis. 40 This central phosphorylation cascade, we have found, includes ubiquitin chain remodeling.
